Takeda Pharmaceutical (TKPHF) Enterprise Value (2017 - 2026)

Takeda Pharmaceutical's Enterprise Value history runs 10 years deep, the most recent figure standing at -$6.6 billion for Q1 2026.

• In Q1 2026, Enterprise Value fell 36.76% year-over-year to -$6.6 billion; the TTM figure through Mar 2026 stood at -$6.6 billion (down 36.76% YoY), while the FY2026 annual figure was -$6.9 billion, down 42.26% from the prior year.
• Enterprise Value was -$6.6 billion for Q1 2026 at Takeda Pharmaceutical, up from -$7.0 billion in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$3.2 billion in Q1 2024 to a low of -$8.8 billion in Q2 2022.
• Historically, Enterprise Value has averaged -$6.1 billion across 5 years, with a median of -$5.9 billion in 2023.
• The sharpest annual moves came in 2023 and 2025: Enterprise Value surged 44.4% in 2023, then sank 51.23% in 2025.
• A 5-year view of Enterprise Value shows it stood at -$8.0 billion in 2022, then surged by 31.75% to -$5.4 billion in 2023, then dropped by 3.55% to -$5.6 billion in 2024, then fell by 24.61% to -$7.0 billion in 2025, then grew by 5.86% to -$6.6 billion in 2026.
• The last three Enterprise Value figures came in at -$6.6 billion (Q1 2026), -$7.0 billion (Q4 2025), and -$7.1 billion (Q3 2025), per Business Quant data.